THEOPHYLLINE (ANHYDROUS)- theophylline tablet, extended release

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

THEOPHYLLINE ANHYDROUS (UNII: 0I55128JYK) (THEOPHYLLINE ANHYDROUS - UNII:0I55128JYK)

から入手可能:

Carilion Materials Management

INN（国際名）:

THEOPHYLLINE ANHYDROUS

構図:

THEOPHYLLINE ANHYDROUS 600 mg

投与経路:

ORAL

処方タイプ:

PRESCRIPTION DRUG

適応症:

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Theophylline (Anhydrous) Extended-Release Tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

製品概要:

Product: 68151-4210 NDC: 68151-4210-0 1 TABLET, EXTENDED RELEASE in a PACKAGE

認証ステータス:

Abbreviated New Drug Application

製品の特徴

THEOPHYLLINE (ANHYDROUS)- THEOPHYLLINE TABLET, EXTENDED RELEASE
CARILION MATERIALS MANAGEMENT
----------
THEOPHYLLINE (ANHYDROUS) EXTENDED-RELEASE TABLETS
DESCRIPTION
Theophylline (Anhydrous) Extended-Release Tablets in a
controlled-release system allows a 24-hour
dosing interval for appropriate patients.
Theophylline is structurally classified as a methylxanthine. It occurs
as a white, odorless, crystalline
powder with a bitter taste. Anhydrous theophylline has the chemical
name 1H-Purine-2,6-dione,3,7-
dihydro-1,3-dimethyl-, and is represented by the following structural
formula:
The molecular formula of anhydrous theophylline is C H N O with a
molecular weight of 180.17.
Each extended-release tablet for oral administration, contains 400 or
600 mg of anhydrous
theophylline.
Inactive ingredients: glyceryl behenate, silicified microcrystalline
cellulose, silicon dioxide, and
magnesium stearate.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION:
Theophylline has two distinct actions in the airways of patients with
reversible obstruction; smooth
muscle relaxation (i.e., bronchodilation) and suppression of the
response of the airways to stimuli (i.e.,
non-bronchodilator prophylactic effects). While the mechanisms of
action of theophylline are not
known with certainty, studies in animals suggest that
bronchodilatation is mediated by the inhibition
of two isozymes of phosphodiesterase (PDE III and, to a lesser extent,
PDE IV) while non-
bronchodilator prophylactic actions are probably mediated through one
or more different
molecular mechanisms, that do not involve inhibition of PDE III or
antagonism of adenosine receptors.
Some of the adverse effects associated with theophylline appear to be
mediated by inhibition of
PDE III (e.g., hypotension, tachycardia, headache, and emesis) and
adenosine receptor antagonism (e.g.,
alterations in cerebral blood flow).
Theophylline increases the force of contraction of diaphragmatic
muscles. This action appears to be
due to enhancement of calcium uptake through an adenosine-mediated
channe